EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
EyePoint Pharmaceuticals (EYPT) Prices 9.1M Share Common Offering at $11/Sh
February 2, 2021 5:48 AM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public... More
Pre-Open Stock Movers 01/28: (KOSS) (HIMS) (EYPT) Higher; (AMC) (BBY) (NOK) (EXPR) Lower (more...)
January 28, 2021 9:29 AM ESTPre-pen Stock Movers
Koss Corporation (NASDAQ: KOSS) 78% HIGHER; adds to recent short-squeeze gains.
AMC Entertainment Holdings, Inc. (NYSE: AMC) 35.4% LOWER; profit-taking after rising 301% intra-day Wednesday on short-squeeze. Trading firms restrict trading.
Him & Hers Health (NYSE:... More
EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
January 28, 2021 7:10 AM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
EYP-1901 leverages the Companys proprietary Durasert® drug delivery technology that has been used in four FDA-approved products, including EyePoints YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye. EYP-1901 uses a bioerodible Durasert formulation combined with a clinically validated anti-VEGF molecule, vorolanib. In oral formulation, vorolanib demonstrated efficacy and... More
